National Fuel Gas Leads 2026 Corporate Earnings Announcements

earnings releases conference calls dividend increase pharmaceuticals technology

National Fuel Gas Company reported third‑quarter fiscal 2026 earnings of $138.6 million, GAAP EPS $1.45 and announced a 4 % dividend increase to $2.22 per share, while confirming the pending Ohio utility acquisition. Antero Resources scheduled its fourth‑quarter 2025 earnings release for February 11 2026 with a conference call on February 12. Amphastar Pharmaceuticals set a second‑quarter 2026 results release for August 6 2026 with a live call. MercadoLibre is expected to post Q2 2026 earnings of $8.67 per share and revenue of $9.74 billion, with a conference call on August 3. Vanda Pharmaceuticals will release its Q2 2026 results on August 5 2026 and hold a call the same day. AbbVie will report second‑quarter 2026 results on July 31, focusing on growth from Skyrizi and Rinvoq amid a post‑Humira transition. Align Technology announced quarterly earnings of $2.64 EPS and $1.06 billion revenue, beating estimates. Nexans filed its semi‑annual 2026 financial report covering results through June 30 2026. Spinal Elements introduced the Luna Ti transforaminal lumbar interbody fusion implant, marking a product launch rather than an earnings filing. Together, these announcements reflect a wave of earnings releases and corporate updates across the energy, pharmaceutical, technology, and industrial sectors in mid‑2026.

Entities: Alphatec Holdings, Inc. · Amphastar Pharmaceuticals, Inc. · Antero Resources Corp. · J. Todd Koning · MercadoLibre, Inc. · National Fuel Gas Company · Robert Judd · Ultragenyx Pharmaceutical Inc. · Vanda Pharmaceuticals Inc.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[○ 1 SOURCE] Analysts expect Alphatec earnings of $0.09 per share and revenue of $211.27 million for Q2 2026. (article 618a4d89-414a-474b-8ea5-5a1f5a45f4fc)
[○ 1 SOURCE] Analysts expect Ultragenyx earnings of –$1.2116 per share and revenue of $183.08 million for Q2 2026. (article a0b0b4ce-21db-423d-8579-a052157deae7)
[○ 1 SOURCE] Alphatec will present at the 19th Annual Piper Sandler MedTech and Diagnostics California Bus Tour on August 19, 2026. (article fb08ba12-9c16-4481-8649-8e339419f439)
[○ 1 SOURCE] Alphatec will release its Q2 2026 earnings after market close on Tuesday, August 4, 2026. (article 618a4d89-414a-474b-8ea5-5a1f5a45f4fc)
[○ 1 SOURCE] Alphatec’s Compensation Committee approved 36 new RSU grants totaling 108,630 restricted stock units. (article fb08ba12-9c16-4481-8649-8e339419f439)
[○ 1 SOURCE] Alphatec will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on September 9, 2026. (article fb08ba12-9c16-4481-8649-8e339419f439)
[○ 1 SOURCE] Alphatec management will hold a one‑on‑one investor meeting at the 11th Annual Needham Virtual MedTech & Diagnostics conference on August 10, 2026. (article fb08ba12-9c16-4481-8649-8e339419f439)
[○ 1 SOURCE] Ultragenyx Pharmaceutical will release its Q2 2026 earnings after market close on Tuesday, August 4, 2026. (article a0b0b4ce-21db-423d-8579-a052157deae7)